

Swedish Hedge Funds Among Institutional Investors in Immunicum Directed Share Issue

Stockholm (HedgeNordic) - Immunicum, a Swedish company said to be creating the blue print for the world's first personalized, off-the-shelf affordable cancer treatment, has decided to implement a directed issue of approximately SEK 178 million and a rights issue of approximately SEK 173 million, according to a press release.

The money to be raised is aimed at continuing to finance the clinical development of the company's immunotherapeutical drug ilixadencel.

Several institutions are among the investors subscribing to the directed issue including three Swedish hedge fund companies; Gladiator, Nordic Cross, and Adrigo. Other institutions include AP2, AP4, and Alfred Berg.

Photo by Louis Reed on Unsplash.